The World of Health & Medicine News

Innogen, Other Chinese Pharmas to Cause Weight-Loss Drug Price Plunge

Innogen, Other Chinese Pharmas to Cause Weight-Loss Drug Price Plunge

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race to develop obesity treatments.

Chinese companies are rushing to develop drugs belonging to the GLP-1 class of medications for weight loss and related conditions as the patent of Novo Nordisk’s semaglutide, a key active ingredient in its best-selling Ozempic and Wegovy drugs, is due to end in early 2026 in China.

“I think the Phase IIB will be out by the end of this year, then Phase III will be (finished) by next year,” Innogen CEO Wang Qinghua told Reuters in an interview about the company’s experimental drug candidate.

Initial results from an early trial, published in June, showed people on the experimental efsubaglutide alfa injection lost about 7% of their body weight after four weeks.

By comparison, large-scale trials over a longer period for Novo’s weight-loss drug Wegovy helped people lose an average 15% of their body weight, according to its clinical trial data.

Wang said the efficacy in Innogen’s experimental injection was not fully visible in the firm’s drug study because of the short evaluation time, adding the company expects to get more significant weight reduction as it continues with more studies.

Chinese regulators have already approved the Shanghai-based company’s self-developed efsubaglutide alfa as a once-weekly injection for the control of Type 2 diabetes in January.

CHEAPER OPTIONS

Yurou Zheng, an analyst at Morningstar, said the near-term challenge for weight-loss drugs in China would be potential price competition, as more drugs are coming online.

“I think many users are more likely to pivot to cheaper options if the efficacy profiles are similar or even slightly less superior as long as they are well within a few percentage points,” he said in a note.

On Friday, Chinese drugmaker Innovent Biologics became the latest local company entering the increasingly crowded weight-loss drug market, saying its treatment mazdutide, which is licensed from Eli Lilly, was approved by the country’s regulators.

The Suzhou-based firm said in June that a Phase III trial showed that after 24 weeks of treatment, 6 mg of mazdutide led to about an 8% change in body weight from baseline.

Underscoring growing competitive pressure in China, India’s Biocon dropped plans to commercialise its weight loss drugs in China, a senior executive told Reuters last week.

spot_img

Explore more

spot_img

WHO launches bold push to raise health taxes and save millions...

WHO launches bold push to raise health taxes and save millions of lives The “3 by 35” Initiative targets tobacco, alcohol, and sugary drinks to...

US CDC accepts ousted vaccine panel’s recommendations for RSV, meningococcal shots

US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a...

NATO fund backs biotech startup in push to counter biological threats

NATO fund backs biotech startup in push to counter biological threats The NATO Innovation Fund has made its first investment in a biotechnology company, it...

It’s too easy to make AI chatbots lie about health information,...

It’s too easy to make AI chatbots lie about health information, study finds Well-known AI chatbots can be configured to routinely answer health queries with...

China Approves First Homegrown GLP-1 Obesity Drug, Challenging Global Giants

China Approves First Homegrown GLP-1 Obesity Drug, Challenging Global Giants Chinese pharmaceutical company Hangzhou Jiuyuan Gene Engineering has received preliminary approval in China for Maibulin, an...

Should you drink ice water in hot weather?

Should you drink ice water in hot weather? Things are hotting up across the U.S. — this past week saw hundreds of record highs broken from...

Exclusive-USAID Cancelled Rape Survivor Kits for Congo as Conflict Erupted

Exclusive-USAID Cancelled Rape Survivor Kits for Congo as Conflict Erupted U.S. President Donald Trump's administration cancelled a major contract to supply emergency kits for rape...

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR...

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis  Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European...